+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Treatment of Piriformis Muscle Syndrome with Botulinum Toxin-A



Treatment of Piriformis Muscle Syndrome with Botulinum Toxin-A



Anesthesiology Abstracts of Scientific Papers Annual Meeting ( ): Abstract No A-879



Piriformis syndrome has been documented as a primary or contributory cause of "sciatica" and low back pain. We present a retrospective review of fifety patients who underwent intrapiriformis muscle botox injection with remarkable pain relief at 6 to 8 weeks follow-up.The demographic characteristics of the study group is given in Table I. Our diagnostic criteria for piriformis muscle syndrome are: Gluteal pain with or without pain radiating down the affected leg in the distribution of sciatic nerve, muscle spasms/pull in leg muscles, positive Beatty's Maneuver with or without the presence of tenderness in buttock, and L5 or S1 sensory nerve root hypoesthesia of A-delta fibers on affected side. V-sNCT, Voltage-Sensitive Nerve Conduction Threshold, is a direct quantitative sensory test (QST), which provides a reproducible (<0.2mA) functional assessment of the peripheral sensory nervous system by measuring that voltage intensity which initiates membrane potential changes, to propagate a nerve impulse. The Botulinum-toxin A used for injection is a standardized preparation. 100 Units of BotoxTM in 5 cc of preservative-free 0.9 N saline was injected into the piriformis muscle,under fluroscopic guidance. Results: All patients reported a reduction in pain score. VAS pain score in the study population (n=50) was 8.87+- 0.15 prior to treatment and 4.5+-0.2 after treatment (p<0.01). McGill score (n=27) was 40.6 +-3.04 before and 21.5 +-2.51 after the injection (p<0.01), Oswestry (n=27) changed from 25.9+- 1.26 to 11.7 +- 1.02(p<0.01) and Roland-Morris (n=27) decreased from 16.0 +- .935 to 20.6+- 1.02 (p<0.01). Discussion Botulinum toxin-A** is a 150 Kda protein neurotoxin,produced by Clostridium botulinum, which acts presynaptically by inhibiting the release of acetylcholine, thus leading to functional denervation of the muscle . This lasts up to 6 months. The piriformis muscle is a pyramidal muscle, which arises from the ventrolateral aspect of the sacrum from S1-S4, gluteal surface of ilium and the anterior capsule of the sacroiliac joint and passes laterally through the greater sciatic foramen to its insertion on greater trochanter of femur. The signs and symptoms of sciatica caused by piriformis syndrome can be explained by the close relationship of the muscle to sciatic nerve at the sciatic notch. A variety of therapeutic approaches have been suggested for the management of piriformis syndrome like analgesics, application of heat, osteopathic manipulation,and even surgical resection of piriformis muscle. Except for the latter, none of these modalities offer significant pain relief, and surgery is associated with morbidity. Ours is the first review where the effect of intrapiriformis muscle botox has been studied. All of our patients who underwent Botox TM injection to piriformis muscle reported a reduction in pain by 45% or more as well as improvement in their disability scores. Therefore we propose that BotoxTM injection to piriformis muscle is an effective treatment for low back pain and sciatica caused by piriformis syndrome.

(PDF emailed within 1 workday: $29.90)

Accession: 035980577

Download citation: RISBibTeXText


Related references

An MRI evaluation of changes in piriformis muscle morphology induced by botulinum toxin injections in the treatment of piriformis syndrome. Diagnostic and Interventional Imaging 96(1): 37-43, 2015

Botulinum Toxin Type A Use in Piriformis Muscle Syndrome. American Journal of Physical Medicine & Rehabilitation 81(10): 751-759, 2002

Botulinum toxin type A use in piriformis muscle syndrome: a pilot study. American Journal of Physical Medicine & Rehabilitation 81(10): 751-759, 2002

Treatment of piriformis syndrome with botulinum toxin. Jost, W H , Reprint Author Botulinum toxin in painful diseases: 140-158, 2003

Botulinum toxin in the treatment of piriformis syndrome The predictive value of d-tubocurare. Regional Anesthesia & Pain Medicine 26(2 Supplement): 102, March-April, 2001

Application/INS; of botulinum toxin type A for piriformis syndrome treatment. Journal of the Neurological Sciences 333: E530-E531, 2013

Low-dose botulinum toxin type A for the treatment of refractory piriformis syndrome. PharmacoTherapy 27(5): 657-665, 2007

Ultrasound-Guided Injection of Botulinum Toxin Type A for Piriformis Muscle Syndrome: A Case Report and Review of the Literature. Toxins 7(8): 3045-3056, 2016

Piriformis muscle syndrome (PMS): Review of diagnostic criteria and therapeutic proposals, including the effect of botulinum toxin, in a series of 32 cases. 2007

Usefulness of Magnetic Resonance Neurography for Diagnosis of Piriformis Muscle Syndrome and Verification of the Effect After Botulinum Toxin Type A Injection: Two Cases. Medicine 94(38): E1504-E1504, 2015

Botulinum toxin type B in piriformis syndrome. American Journal of Physical Medicine & Rehabilitation 83(3): 198-202, 2004

Sciatic perineural edema treated by Botulinum toxin injection on piriformis muscle. Spine Journal 15(7): 1680-1681, 2014

CT-guided piriformis muscle injection for the treatment of piriformis syndrome. Turkish Neurosurgery 24(4): 471-477, 2015

Botulinum Toxin-A for treatment of Pisa syndrome: A new target muscle. Parkinsonism & Related Disorders 21(6): 669-670, 2016

The piriformis muscle syndrome. Sciatic nerve entrapment treated with section of the piriformis muscle. Acta Orthopaedica Scandinavica 52(1): 73-75, 1981